Grail Q3 net loss widens 16% to $103.6 million
- Grail’s third-quarter 2026 net loss widened 16% year-over-year to $103.6 million.
- Total revenue rose to $37.5 million, while Galleri revenue climbed 14% year-over-year to $37.3 million.
- Galleri test volume increased approximately 24% year-over-year to more than 56,000 tests.
- An FDA advisory panel backed Galleri approval in September; a regulatory decision is expected by early Q1 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA89225) on November 04, 2026, and is solely responsible for the information contained therein.